Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Float is probably less than that.Cheeky has it at 3.5 mil.That's not taking into account all the shares owned by people on this board.
QMDT..This one can shoot up thousands of % in an hour or two or about as fast as it takes to churn through an approx 4 million float from retail investors imo
QMDT..On 2011 Q rev's were over 1 BILLION DOLLARS!..Stopped reporting soon afterward..A buyout is underway imo..Why else would the officers be so closed mouthed? Audits and DD for a buyout /merger are being done AS WE SPEAK imo
PARTNERS AVERY DENNISON, BASF, MEDLINE, DERMA SCIENCE, SARASOTA MEDICAL, DORIS, & MORE...Google them....
I am waitng for the buyout/merger u have mentioned.
This will bounce.<<<<QMDT..Agreed-4 Million float demands it!
I loaded up 2.1M shares of QMDT in last few weeks.<<<<QMDT..MMMMk!
QMDT..Bid moving up!
6000 shares traded and down 60 percent to .03<<<<QMDT..Its all good..50K bid didnt budge..Someone trying to accumulate but to get any kind of size they will have to move it up!
6000 shares traded and down 60 percent to .03
Another Big Partner >>>> Sarasota Medical Products to License Stay-Fresh(R) Antimicrobial Technology for Use in Ostomy and Wound Care Products <<<<QMDT..Wonder what additional Rev's that will provide?
Another Big Partner >>>> Sarasota Medical Products to License Stay-Fresh(R) Antimicrobial Technology for Use in Ostomy and Wound Care Products
GAINESVILLE, FL -- (Marketwired) -- 01/14/14 -- Quick-Med Technologies, Inc. (OTCQB: QMDT)(PINKSHEETS: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has licensed its Stay Fresh®technology to Sarasota Medical Products (SMP) for use in Hydrocolloids in SMP's Ostomy and Advanced Wound Care product lines.
"We are very excited to enter this new product segment of hydrocolloids with a partner that is close to home, manufacturing high quality wound care products for global distribution. Our antimicrobial technology will greatly expand the number of patients we can provide with safe, effective antimicrobial products in support of infection prevention and control programs. Our technologies are specifically designed to be effective against resistant organisms like MRSA, and to prevent new resistant bacteria from emerging" said Bernd Liesenfeld, Quick-Med's President. This is the initial commercial application of Quick-Med's newest Stay Fresh format: an antimicrobial superabsorbent powder (SAP) that can be directly substituted for a conventional SAP to provide strong and durable antimicrobial activity in applications including health care and hygiene.
"Hydrocolloids are excellent at maintaining the correct moisture balance to optimize wound closure and healing," notes Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "Stay Fresh antimicrobial activity is based on peroxide, which is the chemical mechanism utilized by the body's own neutrophils to kill invading pathogens, and therefore provides optimum biological safety."
"Sarasota Medical Products manufactures a broad array of premium quality ostomy and advanced wound care products that will now include Quick-Med's Stay Fresh® antimicrobial technology," said Dr. Walt F Leise III, SMP's CEO and President. Sarasota Medical provides product to these markets under a broad range of private labels. The US market for advanced wound care is growing from $3.4 billion in 2010 to an expected $4.6 billion by 2016, and Hydrocolloids represented approximately $800M of the AWC market in 2011.
About Stay Fresh
Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly used in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registeredStay Fresh to be utilized to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has also granted clearance to market an antibacterial medical textile based on Stay Fresh Technology. The Stay Freshtechnology offerings provided by Quick-Med are expanding continuously, with development of additional applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay FreshTechnology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.
About Sarasota Medical Products
Sarasota Medical Products Inc. (SMP) develops and manufactures ostomy and advanced wound care products in Sarasota, FL. SMP has a growing portfolio of proprietary technology to drive next-generation product development in the wound, ostomy and incontinence market segments. SMP specializes in gentle and secure adhesive formulations that are suitable for long or short-term skin wear, and is a leader in developing technologies to deliver medication and active oxygen to chronic wounds. As a contract manufacturer and technology development partner, SMP offers creative, collaborative and custom device design services for medical products. Information: www.sarasotamedical.com
© 2014 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, and Stay Fresh® are registered trademarks of Quick-Med Technologies, Inc.
UPDATED FLOAT 3,590,155 of 33,755,999 O/S >>> Shares Beneficially Owned
Number Percent
Michael R. Granito 23,553,605 (1)
46.5 %
Phronesis Partners, L.P. 8,015,339 (2)
20.3 %
Gerald M. Olderman, Director 799,714 (3)
2.1 %
Gregory S. Schultz, Director 1,310,101 (4)
3.5 %
Bernd Liesenfeld, President and Director 77,000 (5)
0.2 %
Paul H Jenssen, CFO and Director 0 0 %
Dale Bergman, Director 0 %
QMDT..Sweet day..Interest picking up..Getting close to BIG NEWS!
QMDT..BKMM will buy em for 028 and sell em at .55!
Plz STICKY JAN 2015 PATENT APPROVAL...
someone got impatient and wanted a few bucks! got bought right back up. Just need some volume and we are golden pony boy! Every thing is locked up hard!
What the hell happened? I leave for an hour and now were down 25%.
Qmdt..The beautiful thing is..There are no shares.. If there were people would put em up at different prices between 4 and 7 but nothing!
YEP! BOOM BUY! See if we can get someone else to get it up and start the next leg
QMDT..Just some low dollar munipulation..Doesn't change the HUGE value of this company..
that drop/sell off was not expected. need some purchasing pressure.
QMDT..Merger/takeover imo..If company is no longer reporting why be silent? Audit going on IMO Lawyers biling big bucks involved..Making sure "I"s are dotted and "t"s crossed..
What do you think is going on? Are getting close to news?
QMDT..TY..Something is seriously going on in the background..ZERO sells!
I just posted that over at BB stock haven board.
QMDT..Thinning even more..Now only 26 to .137 and MM at 071 moved way up!
QMDT..Thinning out..Now only 32k to .137!
Hopefully something good is coming!
QMDT..Company is dark but not saying a word..What's that tell you?
Whoa! What's going on? How do you go up 77% on 2000 volume?
Soon people will take notice of us here at QMDT and then its go time. Just needs the right news or a PR and BOOOM!
Waiting patiently! QMDT!
QMDT..Nobody is selling..Merger/Buyout coming IMO..That's why they are dark..Lawyers are working..
That large of a spread discourages buying.Who would want to buy at .07 and sell at .02.
QMDT..ZERO shares available-Float locked!
QMDT..Nice gig those MM's have..Buying at 028 and selling at 071 but NOT FOR LONG!
The new polyurethane polycation is well suited for a wide range of applications including plastic films and coatings, adhesives, catheters and other types of extruded tubing. <<<<<QMDT..In my day we only had regular catheters and were damn glad to have em!
Big Article on NIMBUS(QMDT) Medical plastic material and process innovations to watch
Don Rosato
Monday, January 19, 2015
Share this article
Note: This is the second article of a three-part series covering medical plastics (1) trends, (2) material/process advances and (3) applications.
Plastic products designed for applications in medical technology have to meet a number of special criteria. Typically, excellent mechanical properties are required, even in components with small dimensions and wall thicknesses.
In many instances, the medical devices must be germ-free and the materials they are made of must correspondingly be capable of being sterilized. Depending upon the sterilization procedures employed, the plastics used must be able to withstand hot steam or hot air, disinfectants, gamma radiation or ethylene oxide exposure.
Prostheses and implants that are subject to loads on a daily basis, as well as instruments that may injure a patient if defective, must be immune to mechanical accidents caused by material breaking, buckling or fraying. Aside from withstanding sterilization procedures, in many applications it is important for materials to be unaffected when in contact with organic substances or other chemicals in the laboratory.
Let's take a look at some innovative medical plastic material and process developments.
We'll begin with an advance in nonleaching antimicrobial material technology. The global market for healthcare antimicrobial plastics is forecast to reach 220,000 metric tons by the year 2017, fueled by rising demand from healthcare, industrial and consumer end-use sectors.
Stringent government legislation and potential liabilities for service/product related infections are prompting the use of biocidal plastics in healthcare environs. The need to prevent hospital-acquired infection (HAI) and related complications is a major impetus for the development of novel biocides, antimicrobial polymer technologies and innovative applications deploying these solutions.
New and growing medical applications include devices that break through the skin or are inserted into the body including various catheters and needleless connectors. In one study, the incorporation of antimicrobials in venous TPU (thermoplastic polyurethane) catheters used during kidney transplants was shown to significantly reduce infection risk compared to untreated TPU catheters.
NIMBUS, developed by Quick-Med Technologies Inc., is an FDA-cleared, cutting-edge antimicrobial technology custom designed for wound care and medical device applications. The technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation built into the backbone of various polymers.
The nontoxic, long-chain polymers (polycations) with high charge density provide superior efficacy via a physical action on microbes. The advanced cationic, high-molecular-weight antimicrobial polymers attract bacterial cells and bind rapidly to displace calcium ions, thus physically disrupting the cell wall. The cell membrane then collapses, and the cell dies as the cytoplasm leaks out.
High charge density ensures maximum efficacy in the presence of body fluids. As the active agent is permanently bonded to the surface, there is no leaching and no depletion of the antimicrobial reservoir. Additionally, bacteria cannot develop resistance to an agent that they cannot internalize, thus the large size of NIMBUS polymers and their permanent attachment to a surface eliminates the ability of microbes to develop resistance.
Quick-Med Technologies
Three-stage physical method of antimicrobial action.
The company has been granted a range of patents for their NIMBUS technology, covering incorporation of a NIMBUS polycation into the main chain of the polyurethane polymer and the process of attaching NIMBUS antimicrobials to a range of substrates. The new polyurethane polycation is well suited for a wide range of applications including plastic films and coatings, adhesives, catheters and other types of extruded tubing.
The substrates are, in whole or in part, cellulosic or any of a list of other substrates, including polyurethane, polyester, nylon and acrylics, as well as silk, linen, rubber, alginates and collagen. These materials are commonly used in textile and medical products, filters, absorbent products and packaging.
While NIMBUS antimicrobials remain at full strength, the active agent in most other antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the risk of irritation or interference with healing in products such as wound dressings and textile applications when the treated material is next to or used on the skin.
Finally, let's review an advance in the use of fiber lasers in transparent medical plastics welding. As demand for ever-smaller medical devices grows, innovative manufacturing technologies are being adopted to allow for the production of ultraprecise designs.
Joining and assembly by a myriad of techniques including adhesives, hot plate welding, ultrasonic welding and friction welding, each with its own design demand/requirements and advantages/disadvantages, are critical steps in the manufacture of medical plastics devices. Cleanliness, precision, hermetic sealing and quality control are significant advantages of laser welding for the medical industry.
Bonding completed by ultrasonic or friction-welding processes will leave the joint with a scaling effect that is caused by what essentially is rubbing two parts together at high speeds. The scales from the joint break away and become loose, generating dust-like particulates that can contaminate the medical device. Glues and adhesives also have the potential for contamination.
On the other hand, laser welding produces tight, clean joints that are particulate-free. Hermetic sealing of a plastic joint is frequently required for medical devices, whether fluids are to be kept in or out. The excellent fusion of plastics in laser plastics welding ensures strong joints with the weld seam entirely sealed to ensure hermetic sealing.
IPG Photonics
Clean laser weld (left), scaled friction weld (center) and balloon catheter hermetic high strength seal (right).
Traditional laser welding of clear plastics required special expensive, difficult-to-apply infrared absorbers, such as Clearweld infrared inks or Lumogen or Lazenflair dyes, which may be extractable and thus unacceptable for many medical device applications.
Higher-wavelength thulium fiber lasers pioneered by IPG Photonics can be used to laser weld transparent plastics without the need for IR absorber additives, dyes or coatings. Operating in the spectral range of 1800 to 2100 nanometers (nm), these fiber lasers interact differently with plastic than typical 808 or 980 nm IR lasers used in through-transmission welding.
In this wavelength range, you get more absorption in almost all clear polymers because the wavelength is closer to some vibration frequencies of the carbon-hydrogen bond in the given transparent plastic. The technology also allows welding of thermoplastics regardless of polarity, a limitation in some plastics welding systems.
Conventional, nonproprietary radio-frequency welding of films has been limited to polar resins with high dielectric loss factors, particularly flexible PVC and thermoplastic polyurethane (TPU).
IPG Photonics
Melt zone in 20 layers of 0.1-millimeter-thick LDPE welded with 1940 nanometer fiber laser.
Share this article
About the Author
Dr. Donald V. "Don" Rosato serves as president of PlastiSource, Inc. a prototype manufacturing, technology development and marketing advisory firm located in Concord, Mass., and is the author of the Vol 1 & 2 "Plastics Technology Handbook".
2015 1 Patent Granted, 1 Trademark Approved, 2014 Contract with MEDLINE $5.8 Billion Company....Looks like a Huge Sign of LIFE.
But we are in 2015, not 2012? What has happened in the last three years?<<<<<QMDT..The company went dark then out of the blue came out with a PR..PR's cost money so why?
But we are in 2015, not 2012? What has happened in the last three years?
QMDT..Something's gotta give..
MMs upticking, god sign...Dollars coming.
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
732
|
Created
|
03/15/05
|
Type
|
Free
|
Moderators |
QUICK-MED TECHNOLOGIES INC.
http://www.quickmedtech.com/
F.D.A./E.P.A APPROVED/10+ PATENTS + TRADEMARKS
(2019-2030 Expiree Dates)
Competitor Patents Expired
CONTINUOS FUNDING from U.S. ARMY
PARTNERS
AVERY DENNISON of the NYSE @ $50+
BASF of the QX @ $90+
DERMA SCIENCE of the NASDAQ @ $8+
WEXLER, DORIS, POLARTEC, BIOSARA
MEDLINE (Private) $5 Billion+ Annual Sales
$15 BILLION MARKET
MARKET CAP $1,500,000
SHARE STRUCTURE
100,000,000 A/S 37,300,000 O/S
****19,000,000 FLOAT****
18,000,000 RESTRICTED
Quick-Med Technologies, Inc is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets.
The Company’s four core technologies are:
NIMBUS®: a family of advanced polymers bioengineered for antimicrobial, hemostatic, and other properties that can be used in a wide range of medical device applications including wound dressings, medical textiles, catheters, tubing, films and coatings.
Stay Fresh®: a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles.
NimbuDerm™: a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs.
MultiStat®: a family of advanced patented methods and compounds shown to be effective in skin therapy applications.
Quick-Med Technologies, Inc. is a publicly-traded company listed under the symbol "QMDT" on the OTCQB listings of the OTC marketplace.
Dr. Bernd Liesenfeld
President
Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the NIMBUS® technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature NIMBUS dressing. Dr. Liesenfeld received a Ph.D. in Materials Science and Engineering from the University of Florida and holds a Bachelor's degree in Mechanical Engineering and Management from the University of Vermont.
Paul Jenssen
Chief Financial Officer
Mr. Jenssen has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses.
Dr. William Toreki
Vice President, Research & Development
Dr. Toreki joined the Company in 2002 as QMT’s Chief Scientist and is the lead inventor on ten of the Company’s patents. Dr. Toreki received a Ph.D. in Polymer and Analytical Chemistry in 1988 from The University of Florida, and earned a Bachelor’s degree in Chemistry from The University of Delaware in 1982.
Dr. Toreki is an experienced inventor with 20 granted US patents to his credit, and during his tenure at QMT, he has been responsible for the development of three new antimicrobial platforms, including the adaptation of orphaned technology into the new Stay Fresh® antimicrobial system, the NIMBUS® antimicrobial technology that forms the core technology of the company, and the NimbuDerm™ antimicrobial skin protection formulation
http://www.quickmedtech.com/company/board-of-directorsboard-of-directors
Quick-Med’s patented technology, NIMBUS® is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS® received de Novo FDA clearance in June 2009 and has been commercialized in traditional wound care applications. Additional applications under development include advanced wound dressings, medical adhesives, and catheters.
NIMBUS® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUS® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus ("MRSA") and Vancomycin-resistant Enterococcus ("VRE"), two of the most significant antibiotic-resistant organisms responsible for hospital infections.
Unlike any other microbicide on the market today, this cost-effective technology works by creating a non-leaching, permanent bond with a multitude of substrates and is less than 10% the cost of silver-based antimicrobials. NIMBUS® technology enhances the value of treated products and brings dependable, durable and safe antimicrobial protection at extraordinary value—only pennies per product.
Quick-Med has entered licensing agreements with leading wound care companies for NIMBUS® technology with their products. The Company is targeting additional partnerships to apply the NIMBUS® technology in advanced wound care products, catheters, incontinence products and other medical devices
Stay Fresh® Antimicrobial
Stay Fresh® Antimicrobial is a breakthrough antimicrobial textile treatment technology under development for a broad range of applications, including healthcare textiles, commercial uniforms and essential wear.
Stay Fresh Antimicrobial is an EPA-registered product thatoffers material protection for a wide variety of applications, for which a range of solution concentrations are available. The range of application varies widely by intended use, durability requirement, and substrate material.
Stay Fresh Antimicrobial has excellent durability. It imparts durable antimicrobial activity to the surface of a wide variety of substrates. Stay Fresh Antimicrobial suppresses the growth of algae, mold, mildew, fungi and bacteria which cause unpleasant odors, discoloration, staining, deterioration and corrosion.
Stay Fresh® Skin Fold Management Textile
The Stay Fresh Skin Fold Management Textile is an FDA-regulated skin protectant product that provides moisture management to keep skin dry and reduce friction in skin folds and other skin-to-skin contact areas. The Stay Fresh Skin Fold Management Textile contains hydrogen peroxide, which reduces bacterial populations in the fabric. The Stay Fresh Skin Fold Management Textile is a single use product that is custom cut to the desired size from a multiuse roll.
The Stay Fresh Skin Fold Management Textile has been shown to be effective against the following organisms after five days of simulated use conditions, using standard in vitro microbiological methods
NimbuDerm™ is a novel copolymer under development to deliver a breakthrough in hand-hygiene technology. The persistent hand sanitizer has achieved proof-of-principle in providing extraordinarily long lasting antimicrobial protection that is safe, effective, and instant. It reduces bacteria on hands and prevents infections before they develop, contributing to good health, minimizing cost and risk, and saving lives.
NimbuDerm™ has been formulated as a skin-soothing composition, and unlike the alcohol based skin sanitizers available today, it does not lose its efficacy soon after application. NimbuDerm™ can be removed with a soap and water wash, but because it remains active for eight hours, it doesn’t need to be re-applied after every activity. Thus it is kind to the skin.
NimbuDerm™ is effective against MRSA and VRE, two resistant bacterial strains, as well an extensive list of bacteria commonly associated with infections. It acts immediately, reducing the invasive population by 99.99% and has been shown to be 99.9% effective against viral contamination as well.
Like other marketed hand sanitizers, NimbuDerm™ provides rapid protection but it is differentiated by imparting sustained protection for up to eight hours
MultiStat® is Quick-Med’s family of patented compounds and technologies, Matrix Metalloproteinase Inhibitors (MMPIs), that modern research has shown to play a key role in numerous skins conditions, and boasts a broad spectrum of uses including cosmetic and pharmaceutical (consumer, medical, and military).
MultiStat® has demonstrated clinical success in improving the appearance of fine lines and wrinkles resulting from natural aging or sun damage, and has significant benefits in other skin conditions, such as roughness or redness.
MultiStat® is currently an active ingredient in commercially available anti-aging creams.
Ilomastat, a MultiStat®-family compound, is one of the most powerful synthetic MMPI compounds in existence. It has been shown in laboratory testing and in clinical animal models to provide significant protection from vesicant injuries (such as sulfur mustard), and to promote healing after injury in both skin and eyes. The US Army has funded Quick-Med research into the uses of Ilomastat as protective or curative agent against potential terrorist threats from Sulfur Mustard gas, with results demonstrating improved recovery from vesicant eye injury.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |